Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.815 -0.095 (-3.26%)
Streaming Delayed Price Updated: 3:38 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Esperion Therapeutics ↗
 
Via Benzinga
News headline image
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and More 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Looking Into Esperion Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Esperion Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
CLEAR Outcomes Company Update Call: Detailed Results Discussion
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Esperion Therapeutics Q3 Earnings ↗
Esperion Therapeutics (NASDAQ:ESPR) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗
 
Via Benzinga
News headline image
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Picks For 2023: Esperion ↗
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick... 
Via Talk Markets
News headline image
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial ↗
 
Via Benzinga
News headline image
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12... 
Via Benzinga
News headline image
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Hosting Virtual Research & Development Day
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.